The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.
 
Gregory Michael Cote
Consulting or Advisory Role - Advance Medical; InfiniteMD
Research Funding - Agios (Inst); Amgen (Inst); Boston Biomedical (Inst); Epizyme (Inst); Macrogenics (Inst); Otsuka (Inst); PharmaMar (Inst)
 
William Jeffery Edenfield
Speakers' Bureau - Astellas Medivation; Novartis
 
Scott Andrew Laurie
Honoraria - Boehringer Ingelheim; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Nicole Grace Chau
Research Funding - GlaxoSmithKline; Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Carlos Becerra
Honoraria - Taiho Pharmaceutical
Speakers' Bureau - Celgene; Lilly; Taiho Pharmaceutical
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Youzhi Li
Employment - Boston Biomedical
 
Wei Li
Employment - Boston Biomedical
 
Matthew Hitron
Employment - Boston Biomedical
 
Chiang Li
Employment - Boston Biomedical